← Back to Clinical Trials
Recruiting NCT03457402

NCT03457402 Shaping Tolerance for Delayed Rewards

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03457402
Status Recruiting
Phase
Sponsor University of California, Davis
Condition Impulsivity
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2017-09-12
Primary Completion 2026-08

Eligibility & Interventions

Sex All sexes
Min Age 3 Years
Max Age 6 Years
Study Type INTERVENTIONAL
Interventions
Shaping Delay Tolerance

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2017-09-12 with a primary completion date of 2026-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Deficits in self-control are of major public health relevance as they contribute to several negative outcomes for both individuals and society. For children, developing self-control is a critically important step toward success in academic settings and social relationships, yet there are few non-pharmacological approaches that have been successful in increasing self-control. We found in our earlier studies that self-control can be increased in preschool-aged children with high impulsivity by using games in which they practice gradually increasing wait-time for larger, more delayed rewards. We are performing this current study to test if this training to increase self-control can be increased using mobile app technology, with computerized game time being used as a reward.

Eligibility Criteria

Inclusion Criteria: * Age 3-6 years * Hyperactivity/Impulsivity subscale scores of the ADHD Rating Scale-IV Preschool Version (children 3 to 4 years of age) or the Attention and Behavior Scale (children 5 to 6 years of age) ≥ 90th percentile from either the parent or teacher's responses * Physically and visually able to use the tablet, as determined by pre-assessment performance * Children taking psychotropic medication will be included, but must maintain the same medication and dose over the course of the study and for each assessment and exhibit elevated levels of impulsivity based on parent or teacher ratings while medicated. Exclusion Criteria: * Children with autism spectrum disorder and/or intellectual disability (by parent or teacher report or the NIH Toolbox Picture Vocabulary Test).

Contact & Investigator

Central Contact

Samantha Blair, PhD

✉ hs-airlab@ucdavis.edu

📞 916-703-0325

Principal Investigator

Julie Schweitzer, Ph.D.

PRINCIPAL INVESTIGATOR

UC Davis MIND Institute

Frequently Asked Questions

Who can join the NCT03457402 clinical trial?

This trial is open to participants of all sexes, aged 3 Years or older, up to 6 Years, studying Impulsivity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03457402 currently recruiting?

Yes, NCT03457402 is actively recruiting participants. Contact the research team at hs-airlab@ucdavis.edu for enrollment information.

Where is the NCT03457402 trial being conducted?

This trial is being conducted at Sacramento, United States.

Who is sponsoring the NCT03457402 clinical trial?

NCT03457402 is sponsored by University of California, Davis. The principal investigator is Julie Schweitzer, Ph.D. at UC Davis MIND Institute. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology